ARTICLE

FindCenter AddIcon

Ketamine for Depression Still Too Expensive for Widespread Use

By Technology Networks — 2020

A paper authored by researchers from McLean Hospital has determined that esketamine, a nasal spray to treat severe depression, is currently too expensive for widespread use. The study compared the costs and benefits of esketamine, an antidepressant approved by the U.S. Food and Drug Administration (FDA) last year for use in treatment-resistant major depressive disorder.

Read on www.technologynetworks.com

FindCenter Post-Image

Ketamine Therapy Is Going Mainstream. Are We Ready?

The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.

Article
Emily Witt
2021
FindCenter AddIcon
FindCenter Post-Image

Could the Embrace of Psychedelics Lead to a Mental-Health Revolution?

The last time I was on ketamine, I was hooked up to an IV following surgery. This time, the drug—in general medical use as an anesthetic since 1970—arrived on my doorstep courtesy of Mindbloom, a new telemedicine company specializing in ketamine-based psychedelic therapy.

Article
Maya Singer
2021
FindCenter AddIcon
FindCenter Post-Image

Are Psychedelics the Answer to Depression and Addiction?

A new generation of research into psilocybin could change how we treat numerous mental health conditions.

Article
Johann Hari
2018
FindCenter AddIcon
FindCenter Post-Image

An Introduction to Psilocybin

With the advent of the psychedelic renaissance occurring currently, many people have become curious about one of the most famous hallucinogens: psilocybin mushrooms. Read on to discover the most important information about these fascinating fungi.

Article
FindCenter
2022
FindCenter AddIcon
FindCenter Post-Image

It’s Time to Start Studying the Downside of Psychedelics

Before psychedelic therapy and services becomes widely available, there needs to be a better understanding of all the ways these experiences can go wrong.

Article
Shayla Love
2022
FindCenter AddIcon
FindCenter Post-Image

FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression

The FDA is helping to speed up the process of researching and approving psilocybin, a hallucinogenic substance in magic mushrooms, to treat major depressive disorder (MDD).

Article
Yasemin Saplakoglu
2019
FindCenter AddIcon
FindCenter Post-Image

One Dose of ‘Magic Mushroom’ Drug Reduces Anxiety and Depression in Cancer Patients, Study Says

A single dose of psilocybin, a compound found in “magic mushrooms,” provides long-term relief of anxiety and depression in cancer patients, a new study finds.

Article
Meera Senthilingam
2020
FindCenter AddIcon
FindCenter Post-Image

Single Dose of Psychedelic Drug Eased Cancer Patients’ Anxiety, Depression for Years

The new research looked at cancer patients who took part in a study nearly five years ago.

Article
Kaitlin Sullivan
2020
FindCenter AddIcon
FindCenter Post-Image

Meet the Psychologist Using Psychedelics to Treat Racial Trauma

People of color are dealing with racism all the time, in large and small ways, and even dealing with racism in healthcare, even dealing with racism in therapy.

Article
Robin Donovan
2021
FindCenter AddIcon
FindCenter Post-Image

Psychedelic Therapy and Racial Trauma: Offering Clients a Deeper Experience of Healing

Like most people of color in the United States, psychotherapist and researcher Monnica Williams has experienced myriad forms of racism. Early in her career, understanding its effects on her mind and body motivated her to help clients address their own racial trauma in therapy.

Article
Chris Lyford
2021
FindCenter AddIcon

EXPLORE TOPIC

Clinical Depression